Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases

NeuroMolecular Medicine

Volumn 15, Issue 1, 2013, Pages 169-179

  Nutu, Magdalena ^a   Bourgeois, Philippe ^b   Zetterberg, Henrik ^a   Portelius, Erik ^a   Andreasson, Ulf ^a   Parent, Stéphane ^b   Lipari, Francesco ^b   Hall, Sara ^c,d   Constantinescu, Radu ^e   Hansson, Oskar ^a,c,d   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e Sahlgrenka University Hospital   (Sweden)

Author keywords

A ; AD; AlphaLISA; Amyloid; PD

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-16]; CARBOXYPEPTIDASE; EPITOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY DETECTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; RELIABILITY; SHY DRAGER SYNDROME;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; BIOTINYLATION; CARBOXYPEPTIDASES; CATTLE; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPES; FEMALE; FETAL BLOOD; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; REAGENT KITS, DIAGNOSTIC;

BOVINAE; PARKINSONIA;

EID: 84874678235     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-012-8208-8     Document Type: Article

References (71)

1. Abdo, W. F.; De Jong, D.; Hendriks, J. C.; Horstink, M. W.; Kremer, B. P.; Bloem, B. R.; et al. (2004). Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. Movement Disorders, 19(5), 571-579.
2. Aerts, M. B.; Esselink, R. A.; Bloem, B. R.; & Verbeek, M. M. (2011). Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Movement Disorders, 26(1), 169-173.
3. Almkvist, O.; Basun, H.; Wagner, S. L.; Rowe, B. A.; Wahlund, L. O.; & Lannfelt, L. (1997). Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation. Archives of Neurology, 54(5), 641-644. (Pubitemid 27204251)
4. American Psychiatric Association.; A. P. A. (1987). Diagnostic and statistical manual of mental disorders, Third Edition, Revised. Washington D.C.
5. Andreasen, N.; Gottfries, J.; Vanmechelen, E.; Vanderstichele, H.; Davidson, P.; Blennow, K.; et al. (2001). Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 71(4), 557-558. (Pubitemid 32906890)
6. Andreasson, U.; Portelius, E.; Andersson, M. E.; Blennow, K.; & Zetterberg, H. (2007). Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomarkers in Medicine, 1(1), 59-78.
7. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; & Jones, E. (2011). Alzheimer's disease. Lancet, 377(9770), 1019-1031.
8. Bateman, R. J.; Siemers, E. R.; Mawuenyega, K. G.; Wen, G.; Browning, K. R.; Sigurdson, W. C.; et al. (2009). A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Annals of Neurology, 66(1), 48-54.
9. Bjerke, M.; Zetterberg, H.; Edman, A.; Blennow, K.; Wallin, A.; & Andreasson, U. (2011). Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. Journal of Alzheimers Disease, 27(3), 665-676.
10. Blennow, K. (2004). Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx, 1(2), 213-225. (Pubitemid 46589353)
11. Blennow, K.; & Hampel, H. (2003). CSF markers for incipient Alzheimer's disease. Lancet Neurology, 2(10), 605-613. (Pubitemid 37162569)
12. Blennow, K.; Hampel, H.; Weiner, M.; & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature Reviews. Neurology, 6(3), 131-144.
13. Braak, H.; Braak, E.; Yilmazer, D.; de Vos, R. A.; Jansen, E. N.; & Bohl, J. (1996). New aspects of pathology in Parkinson's disease with concomitant incipient Alzheimer's disease. Journal of Neural Transmission. Supplementum, 48, 1-6. (Pubitemid 26423342)
14. Brinkmalm, G.; Portelius, E.; Ohrfelt, A.; Mattsson, N.; Persson, R.; Gustavsson, M. K.; et al. (2012). An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid beta and amyloid precursor protein in human and cat cerebrospinal fluid. Journal of Mass Spectrometry, 47(5), 591-603.
15. Cook, J. J.; Wildsmith, K. R.; Gilberto, D. B.; Holahan, M. A.; Kinney, G. G.; Mathers, P. D.; et al. (2010). Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. Journal of Neuroscience, 30(19), 6743-6750.
16. De Strooper, B. (2010). Proteases and proteolysis in Alzheimer disease: A multifactorial view on the disease process. Physiological Reviews, 90(2), 465-494.
17. Eckman, E. A.; & Eckman, C. B. (2005). Abeta-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochemical Society Transactions, 33(Pt 5), 1101-1105. (Pubitemid 41659123)
18. Eller, M.; & Williams, D. R. (2011). Alpha-synuclein in Parkinson disease and other neurodegenerative disorders. Clinical Chemistry and Laboratory Medicine, 49(3), 403-408.
19. Emre, M.; Aarsland, D.; Brown, R.; Burn, D. J.; Duyckaerts, C.; Mizuno, Y.; et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 22(12), 1689-1707; quiz 1837. (Pubitemid 47597592)
20. Galasko, D.; Chang, L.; Motter, R.; Clark, C. M.; Kaye, J.; Knopman, D.; et al. (1998). High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Archives of Neurology, 55(7), 937-945. (Pubitemid 28335112)
21. Gelb, D. J.; Oliver, E.; & Gilman, S. (1999). Diagnostic criteria for Parkinson disease. Archives of Neurology, 56(1), 33-39. (Pubitemid 29046907)
22. Gilman, S.; Low, P. A.; Quinn, N.; Albanese, A.; Ben-Shlomo, Y.; Fowler, C. J.; et al. (1999). Consensus statement on the diagnosis of multiple system atrophy. Journal of the Neurological Sciences, 163(1), 94-98. (Pubitemid 29155424)
23. Hall, S.; Öhrfelt, A.; Constantinescu, R.; Andreasson, U.; Surova, Y.; Boström, F.; et al. (2012). A panel of five CSF biomarker can be used with high accuracy in the differential diagnosis of patients with dementia and/or Parkinsonism. Archives of Neurology.
24. Hampel, H.; Frank, R.; Broich, K.; Teipel, S. J.; Katz, R. G.; Hardy, J.; et al. (2010). Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives. Nature Reviews Drug Discovery, 9(7), 560-574.
25. Hansson, O.; Zetterberg, H.; Buchhave, P.; Andreasson, U.; Londos, E.; Minthon, L.; et al. (2007). Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dementia and Geriatric Cognitive Disorders, 23(5), 316-320. (Pubitemid 46631938)
26. Hendriks, D.; Scharpe, S.; van Sande, M.; & Lommaert, M. P. (1989). Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. Journal of Clinical Chemistry and Clinical Biochemistry, 27(5), 277-285. (Pubitemid 19140199)
27. Jellinger, K. A. (1997). Morphological substrates of dementia in Parkinsonism. A critical update. Journal of Neural Transmission, Suppl 51, 57-82.
28. Kouri, N.; Whitwell, J. L.; Josephs, K. A.; Rademakers, R.; & Dickson, D. W. (2011). Corticobasal degeneration: A pathologically distinct 4R tauopathy. Nature Review Neurology, 7(5), 263-272.
29. Kuhn, P. H.; Wang, H.; Dislich, B.; Colombo, A.; Zeitschel, U.; Ellwart, J. W.; et al. (2010). ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO Journal, 29(17), 3020-3032.
30. Litvan, I.; Agid, Y.; Calne, D.; Campbell, G.; Dubois, B.; Duvoisin, R. C.; et al. (1996a). Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology, 47(1), 1-9. (Pubitemid 26243849)
31. Litvan, I.; Hauw, J. J.; Bartko, J. J.; Lantos, P. L.; Daniel, S. E.; Horoupian, D. S.; et al. (1996b). Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. Journal of Neuropathology and Experimental Neurology, 55(1), 97-105. (Pubitemid 26013790)
32. Marquez-Curtis, L.; Jalili, A.; Deiteren, K.; Shirvaikar, N.; Lambeir, A. M.; & Janowska-Wieczorek, A. (2008). Carboxypeptidase M expressed by human bone marrow cells cleaves the C-terminal lysine of stromal cell-derived factor-1alpha: Another player in hematopoietic stem/progenitor cell mobilization? Stem Cells, 26(5), 1211-1220.
33. Masters, C. L.; Simms, G.; Weinman, N. A.; Multhaup, G.; McDonald, B. L.; & Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 82(12), 4245-4249. (Pubitemid 15053619)
34. Matsumoto, A.; Itoh, K.; & Matsumoto, R. (2000). A novel carboxypeptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. European Journal of Neuroscience, 12(1), 227-238. (Pubitemid 30068427)
35. Matsumoto, A.; Itoh, K.; Seki, T.; Motozaki, K.; & Matsuyama, S. (2001). Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons. European Journal of Neuroscience, 13(9), 1653-1657. (Pubitemid 32488055)
36. McKeith, I. G.; Burn, D. J.; Ballard, C. G.; Collerton, D.; Jaros, E.; Morris, C. M.; et al. (2003). Dementia with Lewy bodies. Seminars in Clinical Neuropsychiatry, 8(1), 46-57. (Pubitemid 36828251)
37. McKeith, I. G.; Dickson, D. W.; Lowe, J.; Emre, M.; O'Brien, J. T.; Feldman, H.; et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology, 65(12), 1863-1872. (Pubitemid 43970103)
38. McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34(7), 939-944. (Pubitemid 14076461)
39. Mehta, P. D.; Pirttila, T.; Mehta, S. P.; Sersen, E. A.; Aisen, P. S.; & Wisniewski, H. M. (2000). Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Archives of Neurology, 57(1), 100-105. (Pubitemid 30027637)
40. Mollenhauer, B.; Cullen, V.; Kahn, I.; Krastins, B.; Outeiro, T. F.; Pepivani, I.; et al. (2008). Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology, 213(2), 315-325.
41. Olsson, A.; Hoglund, K.; Sjogren, M.; Andreasen, N.; Minthon, L.; Lannfelt, L.; et al. (2003). Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Experimental Neurology, 183(1), 74-80. (Pubitemid 37075858)
42. Oshima, G.; Kato, J.; & Erdos, E. G. (1975). Plasma carboxypeptidase N, subunits and characteristics. Archives of Biochemistry and Biophysics, 170(1), 132-138.
43. Portelius, E.; Andreasson, U.; Ringman, J. M.; Buerger, K.; Daborg, J.; Buchhave, P.; et al. (2010a). Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration, 5, 2.
44. Portelius, E.; Dean, R. A.; Gustavsson, M. K.; Andreasson, U.; Zetterberg, H.; Siemers, E.; et al. (2010b). A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimer's Research & Therapy, 2(2), 7.
45. Portelius, E.; Price, E.; Brinkmalm, G.; Stiteler, M.; Olsson, M.; Persson, R.; et al. (2011). A novel pathway for amyloid precursor protein processing. Neurobiology of Aging, 32(6), 1090-1098.
46. Portelius, E.; Tran, A. J.; Andreasson, U.; Persson, R.; Brinkmalm, G.; Zetterberg, H.; et al. (2007). Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. Journal of Proteome Research, 6(11), 4433-4439. (Pubitemid 350158518)
47. Portelius, E.; Van Broeck, B.; Andreasson, U.; Gustavsson, M. K.; Mercken, M.; Zetterberg, H.; et al. (2010c). Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. Journal of Alzheimer's disease, 21(3), 1005-1012.
48. Portelius, E.; Zetterberg, H.; Andreasson, U.; Brinkmalm, G.; Andreasen, N.; Wallin, A.; et al. (2006). An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neuroscience Letters, 409(3), 215-219. (Pubitemid 44648565)
49. Portelius, E.; Zetterberg, H.; Dean, R. A.; Marcil, A.; Bourgeois, P.; Nutu, M.; et al. (2012). Amyloid-beta1-15/16 as a marker for gamma-secretase inhibition in Alzheimer's Disease. Journal of Alzheimers Disease.
50. Portelius, E.; Zhang, B.; Gustavsson, M. K.; Brinkmalm, G.; Westman-Brinkmalm, A.; Zetterberg, H.; et al. (2009). Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease. Neurodegeneration Disease, 6(5-6), 258-262.
51. Rangan, S. K.; Liu, R.; Brune, D.; Planque, S.; Paul, S.; & Sierks, M. R. (2003). Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry, 42(48), 14328-14334. (Pubitemid 37499430)
52. Rebeiz, J. J.; Kolodny, E. H.; & Richardson, E. P.; Jr. (1968). Corticodentatonigral degeneration with neuronal achromasia. Archives of Neurology, 18(1), 20-33.
53. Santacruz, K.; Pahwa, R.; Lyons, K.; Troster, A.; Handler, M.; Koller, WC.; et al (1999). Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson's disease patients with and without dementia. Neurology, 52 (Suppl. 2)(A476).
54. Schoonenboom, N. S.; Mulder, C.; Van Kamp, G. J.; Mehta, S. P.; Scheltens, P.; Blankenstein, M. A.; et al. (2005). Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: More of the same? Annuals of Neurology, 58(1), 139-142. (Pubitemid 40962469)
55. Sharples, R. A.; Vella, L. J.; Nisbet, R. M.; Naylor, R.; Perez, K.; Barnham, K. J.; et al. (2008). Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J, 22(5), 1469-1478. (Pubitemid 351656787)
56. Skidgel, R. A. (1996). Structure and function of mammalian zinc carboxypeptidase. In N. M. Hooper (Ed.), Zinc metalloprotease in health and disease. London: Taylor & Francis, pp. 241-283.
57. Steele, J. C.; Richardson, J. C.; & Olszewski, J. (1964). Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, Nuchal Dystonia and Dementia. Archives of Neurology, 10, 333-359.
58. Stomrud, E.; Bjorkqvist, M.; Janciauskiene, S.; Minthon, L.; & Hansson, O. (2010). Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimers Research Therapy, 2(3), 20.
59. Sussmuth, S. D.; Uttner, I.; Landwehrmeyer, B.; Pinkhardt, E. H.; Brettschneider, J.; Petzold, A.; et al. (2010). Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes. Movement Disorders, 25(9), 1284-1288.
60. Szekeres, P. G.; Leong, K.; Day, T. A.; Kingston, A. E.; & Karran, E. H. (2008). Development of homogeneous 384-well high-throughput screening assays for Abeta1-40 and Abeta1-42 using AlphaScreen technology. Journal of Biomolecular Screening, 13(2), 101-111. (Pubitemid 351248691)
61. Tjernberg, L. O.; Callaway, D. J.; Tjernberg, A.; Hahne, S.; Lilliehook, C.; Terenius, L.; et al. (1999). A molecular model of Alzheimer amyloid beta-peptide fibril formation. Journal of Biological Chemistry, 274(18), 12619-12625. (Pubitemid 29215498)
62. Tokuda, T.; Salem, S. A.; Allsop, D.; Mizuno, T.; Nakagawa, M.; Qureshi, M. M.; et al. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochemical and Biophysical Research Communications, 349(1), 162-166. (Pubitemid 44331776)
63. Vanderstichele, H.; Van Kerschaver, E.; Hesse, C.; Davidsson, P.; Buyse, M. A.; Andreasen, N.; et al. (2000). Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid, 7(4), 245-258.
64. Vigo-Pelfrey, C.; Lee, D.; Keim, P.; Lieberburg, I.; & Schenk, D. B. (1993). Characterization of beta-amyloid peptide from human cerebrospinal fluid. Journal of Neurochemistry, 61(5), 1965-1968. (Pubitemid 23317227)
65. Wang, W.; Hendriks, D. F.; & Scharpe, S. S. (1994). Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. Journal of Biological Chemistry, 269(22), 15937-15944. (Pubitemid 24202197)
66. Weidemann, A.; Eggert, S.; Reinhard, F. B.; Vogel, M.; Paliga, K.; Baier, G.; et al. (2002). A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with notch processing. Biochemistry, 41(8), 2825-2835. (Pubitemid 34168952)
67. Wiltfang, J.; Esselmann, H.; Bibl, M.; Smirnov, A.; Otto, M.; Paul, S.; et al. (2002). Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. Journal of Neurochemistry, 81(3), 481-496. (Pubitemid 34809327)
68. Wong, C. W.; Quaranta, V.; & Glenner, G. G. (1985). Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proceedings of the National Academy of Sciences of the United States of America, 82(24), 8729-8732. (Pubitemid 16101117)
69. Yu, C.; Kim, S. H.; Ikeuchi, T.; Xu, H.; Gasparini, L.; Wang, R.; et al. (2001). Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma-secretase processing of the APP and Notch1 transmembrane domains. Journal of Biological Chemistry, 276(47), 43756-43760.
70. Zhang, J.; Sokal, I.; Peskind, E. R.; Quinn, J. F.; Jankovic, J.; Kenney, C.; et al. (2008). CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. American Journal of Clinical Pathology, 129(4), 526-529. (Pubitemid 352029270)
71. Zhao, G.; Mao, G.; Tan, J.; Dong, Y.; Cui, M. Z.; Kim, S. H.; et al. (2004). Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. Journal of Biological Chemistry, 279(49), 50647-50650. (Pubitemid 40017799)